Cargando…

Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial

OBJECTIVE: To determine whether silastic ring laparoscopic Roux-en-Y gastric bypass (SR-LRYGB) or laparoscopic sleeve gastrectomy (LSG) produces superior diabetes remission at 5 years. RESEARCH DESIGN AND METHODS: In a single-center, double-blind trial, 114 adults with type 2 diabetes and BMI 35–65...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Rinki, Plank, Lindsay D., Clarke, Michael G., Evennett, Nicholas J., Tan, James, Kim, David D.W., Cutfield, Richard, Booth, Michael W.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274222/
https://www.ncbi.nlm.nih.gov/pubmed/35554515
http://dx.doi.org/10.2337/dc21-2498
_version_ 1784745260023283712
author Murphy, Rinki
Plank, Lindsay D.
Clarke, Michael G.
Evennett, Nicholas J.
Tan, James
Kim, David D.W.
Cutfield, Richard
Booth, Michael W.C.
author_facet Murphy, Rinki
Plank, Lindsay D.
Clarke, Michael G.
Evennett, Nicholas J.
Tan, James
Kim, David D.W.
Cutfield, Richard
Booth, Michael W.C.
author_sort Murphy, Rinki
collection PubMed
description OBJECTIVE: To determine whether silastic ring laparoscopic Roux-en-Y gastric bypass (SR-LRYGB) or laparoscopic sleeve gastrectomy (LSG) produces superior diabetes remission at 5 years. RESEARCH DESIGN AND METHODS: In a single-center, double-blind trial, 114 adults with type 2 diabetes and BMI 35–65 kg/m(2) were randomly assigned to SR-LRYGB or LSG (1:1; stratified by age-group, BMI group, ethnicity, diabetes duration, and insulin therapy) using a web-based service. Diabetes and other metabolic medications were adjusted according to a prespecified protocol. The primary outcome was diabetes remission assessed at 5 years, defined by HbA(1c) <6% (42 mmol/mol) without glucose-lowering medications. Secondary outcomes included changes in weight, cardiometabolic risk factors, quality of life, and adverse events. RESULTS: Diabetes remission after SR-LRYGB versus LSG occurred in 25 (47%) of 53 vs. 18 (33%) of 55 patients (adjusted odds ratios 4.5 [95% CI 1.6, 15.5; P = 0.009] and 4.2 [1.3, 13.4; P = 0.015] in the intention-to-treat analysis). Percent body weight loss was greater after SR-LRYGB than after LSG (absolute difference 10.7%; 95% CI 7.3, 14.0; P < 0.001). Improvements in cardiometabolic risk factors were similar, but HDL cholesterol increased more after SR-LRYGB. Early and late complications were similar in both groups. General health and physical functioning improved after both types of surgery, with greater improvement in physical functioning after SR-LRYGB. People of Māori or Pacific ethnicity (26%) had lower incidence of diabetes remission than those of New Zealand European or other ethnicities (2 of 25 vs. 41 of 83; P < 0.001). CONCLUSIONS: SR-LRYGB provided superior diabetes remission and weight loss compared with LSG at 5 years, with similar low risks of complications.
format Online
Article
Text
id pubmed-9274222
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-92742222022-07-28 Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial Murphy, Rinki Plank, Lindsay D. Clarke, Michael G. Evennett, Nicholas J. Tan, James Kim, David D.W. Cutfield, Richard Booth, Michael W.C. Diabetes Care Clinical Care/Education/Nutrition/Psychosocial Research OBJECTIVE: To determine whether silastic ring laparoscopic Roux-en-Y gastric bypass (SR-LRYGB) or laparoscopic sleeve gastrectomy (LSG) produces superior diabetes remission at 5 years. RESEARCH DESIGN AND METHODS: In a single-center, double-blind trial, 114 adults with type 2 diabetes and BMI 35–65 kg/m(2) were randomly assigned to SR-LRYGB or LSG (1:1; stratified by age-group, BMI group, ethnicity, diabetes duration, and insulin therapy) using a web-based service. Diabetes and other metabolic medications were adjusted according to a prespecified protocol. The primary outcome was diabetes remission assessed at 5 years, defined by HbA(1c) <6% (42 mmol/mol) without glucose-lowering medications. Secondary outcomes included changes in weight, cardiometabolic risk factors, quality of life, and adverse events. RESULTS: Diabetes remission after SR-LRYGB versus LSG occurred in 25 (47%) of 53 vs. 18 (33%) of 55 patients (adjusted odds ratios 4.5 [95% CI 1.6, 15.5; P = 0.009] and 4.2 [1.3, 13.4; P = 0.015] in the intention-to-treat analysis). Percent body weight loss was greater after SR-LRYGB than after LSG (absolute difference 10.7%; 95% CI 7.3, 14.0; P < 0.001). Improvements in cardiometabolic risk factors were similar, but HDL cholesterol increased more after SR-LRYGB. Early and late complications were similar in both groups. General health and physical functioning improved after both types of surgery, with greater improvement in physical functioning after SR-LRYGB. People of Māori or Pacific ethnicity (26%) had lower incidence of diabetes remission than those of New Zealand European or other ethnicities (2 of 25 vs. 41 of 83; P < 0.001). CONCLUSIONS: SR-LRYGB provided superior diabetes remission and weight loss compared with LSG at 5 years, with similar low risks of complications. American Diabetes Association 2022-07-07 2022-05-12 /pmc/articles/PMC9274222/ /pubmed/35554515 http://dx.doi.org/10.2337/dc21-2498 Text en © 2022 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
spellingShingle Clinical Care/Education/Nutrition/Psychosocial Research
Murphy, Rinki
Plank, Lindsay D.
Clarke, Michael G.
Evennett, Nicholas J.
Tan, James
Kim, David D.W.
Cutfield, Richard
Booth, Michael W.C.
Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial
title Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial
title_full Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial
title_fullStr Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial
title_full_unstemmed Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial
title_short Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial
title_sort effect of banded roux-en-y gastric bypass versus sleeve gastrectomy on diabetes remission at 5 years among patients with obesity and type 2 diabetes: a blinded randomized clinical trial
topic Clinical Care/Education/Nutrition/Psychosocial Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274222/
https://www.ncbi.nlm.nih.gov/pubmed/35554515
http://dx.doi.org/10.2337/dc21-2498
work_keys_str_mv AT murphyrinki effectofbandedrouxenygastricbypassversussleevegastrectomyondiabetesremissionat5yearsamongpatientswithobesityandtype2diabetesablindedrandomizedclinicaltrial
AT planklindsayd effectofbandedrouxenygastricbypassversussleevegastrectomyondiabetesremissionat5yearsamongpatientswithobesityandtype2diabetesablindedrandomizedclinicaltrial
AT clarkemichaelg effectofbandedrouxenygastricbypassversussleevegastrectomyondiabetesremissionat5yearsamongpatientswithobesityandtype2diabetesablindedrandomizedclinicaltrial
AT evennettnicholasj effectofbandedrouxenygastricbypassversussleevegastrectomyondiabetesremissionat5yearsamongpatientswithobesityandtype2diabetesablindedrandomizedclinicaltrial
AT tanjames effectofbandedrouxenygastricbypassversussleevegastrectomyondiabetesremissionat5yearsamongpatientswithobesityandtype2diabetesablindedrandomizedclinicaltrial
AT kimdaviddw effectofbandedrouxenygastricbypassversussleevegastrectomyondiabetesremissionat5yearsamongpatientswithobesityandtype2diabetesablindedrandomizedclinicaltrial
AT cutfieldrichard effectofbandedrouxenygastricbypassversussleevegastrectomyondiabetesremissionat5yearsamongpatientswithobesityandtype2diabetesablindedrandomizedclinicaltrial
AT boothmichaelwc effectofbandedrouxenygastricbypassversussleevegastrectomyondiabetesremissionat5yearsamongpatientswithobesityandtype2diabetesablindedrandomizedclinicaltrial